Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Ma J, Waxman DJ.

Mol Cancer Ther. 2008 Jan;7(1):79-89. doi: 10.1158/1535-7163.MCT-07-0584.

3.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI.

Lancet Oncol. 2007 Nov;8(11):975-84. Epub 2007 Oct 23.

PMID:
17959415
5.

Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Chen CS, Jounaidi Y, Su T, Waxman DJ.

Cancer Gene Ther. 2007 Dec;14(12):935-44. Epub 2007 Sep 14.

6.

Autocrine VEGF signaling is required for vascular homeostasis.

Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML.

Cell. 2007 Aug 24;130(4):691-703.

7.

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM.

Clin Cancer Res. 2007 Jul 1;13(13):3942-50.

8.

Angiogenesis: an organizing principle for drug discovery?

Folkman J.

Nat Rev Drug Discov. 2007 Apr;6(4):273-86. Review.

PMID:
17396134
9.
10.
11.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.

Cancer Cell. 2007 Jan;11(1):83-95.

12.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group.

N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.

13.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

14.

Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.

Ansiaux R, Baudelet C, Jordan BF, Crokart N, Martinive P, DeWever J, Grégoire V, Feron O, Gallez B.

Cancer Res. 2006 Oct 1;66(19):9698-704.

15.

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS.

Science. 2006 Sep 22;313(5794):1785-7.

16.

Angiogenesis in malignant glioma--a target for antitumor therapy?

Tuettenberg J, Friedel C, Vajkoczy P.

Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93. Epub 2006 Jul 24. Review.

PMID:
16860996
17.

Predicting benefit from anti-angiogenic agents in malignancy.

Jubb AM, Oates AJ, Holden S, Koeppen H.

Nat Rev Cancer. 2006 Aug;6(8):626-35. Epub 2006 Jul 13. Review.

PMID:
16837971
18.

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

Kerbel RS.

Science. 2006 May 26;312(5777):1171-5.

PMID:
16728631
19.

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.

Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS.

Cancer Res. 2006 Apr 1;66(7):3639-48.

20.

Supplemental Content

Support Center